Sophia Lee, MD
Hematology & Oncology · Houston, TXNPI 1588151401
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,085 of the $5,845 with a category attached, or 87.0%. It is spread thinly across 40 manufacturers, the largest accounting for just 10.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,874, more than ten times the $115 reported in 2021.
Across 112 payments — averaging $52.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$586
- Lilly USA, LLC$474
- GSK$456
- Revance Therapeutics, Inc.$384
- Seagen Inc.$348
- Jazz Pharmaceuticals Inc.$326
- plus $3K from 34 others
What the payments were for
- Food & beverage$5,08587%
- Education$76013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 9 | $586 |
| Lilly USA, LLC | 11 | $474 |
| GSK | 7 | $456 |
| Revance Therapeutics, Inc. | 7 | $384 |
| Seagen Inc. | 3 | $348 |
| Jazz Pharmaceuticals Inc. | 4 | $326 |
| Rigel Pharmaceuticals, Inc. | 4 | $318 |
| Gilead | 3 | $269 |
| AVEO Pharmaceuticals, Inc. | 4 | $244 |
| E.r. Squibb & Sons, L.L.C. | 4 | $227 |
| Merz North America, Inc. | 2 | $220 |
| Sanofi | 3 | $219 |
| Johnson & Johnson | 4 | $212 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $156 |
| Stemline Therapeutics Inc. | 2 | $149 |
| Pharmaessentia USA Corporation | 2 | $148 |
| Pfizer | 5 | $121 |
| Myriad Genetic Laboratories, Inc. | 2 | $95 |
| AbbVie | 4 | $92 |
| AstraZeneca | 4 | $88 |
| Daiichi Sankyo Inc. | 3 | $81 |
| Merck | 3 | $78 |
| Astellas Pharma US Inc | 1 | $70 |
| Bristol Myers Squibb | 2 | $49 |
| Sobi, Inc | 1 | $47 |
| Galderma Laboratories, L.p. | 1 | $39 |
| Blueprint Medicines Corporation | 1 | $34 |
| Regeneron | 1 | $33 |
| Beigene USA, Inc. | 1 | $31 |
| Novartis | 1 | $31 |
| Tersera Therapeutics LLC | 1 | $29 |
| Deciphera Pharmaceuticals Inc. | 1 | $28 |
| Geron Corporation | 1 | $27 |
| Springworks Therapeutics, Inc. | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Beone Medicines USA, Inc. | 1 | $23 |
| Genmab U.S., Inc. | 1 | $20 |
| Exelixis Inc. | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,845 in reported general payments places this provider in the 60th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.